Idiopathic pulmonary fibrosis: a clinical update.

J Shaw, T Marshall, H Morris, N Chaudhuri

Research output: Contribution to journalArticlepeer-review


Idiopathic pulmonary fibrosis (IPF) is the commonest interstitial lung disease (ILD) and is characterised by progressive scarring of the lungs. It typically presents in the sixth or seventh decade.1 The prognosis of IPF is poor and is worse than most cancers, with a median survival from diagnosis of 2.5–3.5 years.1 In 2012, over 5000 people died of IPF in the UK accounting for 1% of all deaths and 4.6% of respiratory deaths.2 On average, a general practice of 10 000 patients will see 2–3 new cases every 3 years,3 although this is likely to be an underestimate, contrasting with 500 per 10 000 for chronic obstructive pulmonary disease (COPD). The rising incidence and prevalence means that GPs will be pivotal in the early detection and long-term management of patients with IPF.
Original languageEnglish
JournalThe British journal of general practice : the journal of the Royal College of General Practitioners
Early online date26 Apr 2018
Publication statusPublished - May 2018


Dive into the research topics of 'Idiopathic pulmonary fibrosis: a clinical update.'. Together they form a unique fingerprint.

Cite this